Hawaii Biotech regained an exclusive license from Merck Sharp & Dohme, a unit of Merck & Co., for technology it had invented to produce vaccines for malaria and tick-borne encephalitis. The Merck unit also granted Hawaii Biotech nonexclusive rights for a recombinant protein expression platform. Merck Sharp & Dohme gained access to the products when it acquired Hawaii Biotech's dengue fever vaccine last year.

Related Summaries